Thinking up tomorrow's medicine
IGNA, multidisciplinary laboratory of criminal expertise, celebrated its 10th anniversary last year. Stemming from Nantes University Hospital, it was created in 2003 by Professor Jean-Paul Moisan. After his accidental death in 2012, the company's reins were taken over by two of his colleagues, experts in DNA: Soizic Le Guiner and Marie-Gaëlle Le Pajolec. With a presence in Nantes (55 people) and in Marseille (6 persons), IGNA pursues a multidisciplinary path in order to follow an holistic approach and a perpetual innovation, both of which guarantee the quality of its services.
The French Institute awards its annual “Janus” label to the most creative achievements in the fields of design. The “Janus” jury selects products and services that prioritize respect for the user and his environment. For the 2014 edition, 11 companies, including AWEL, were certified. AWEL is particularly recognized for its gravimetric diluter.
The announcement was made Sunday, November 9th on “France Info” by Caroline Guiner of the Nantes Institute: Atlantic Gene Therapies. She is the first author of a study published in the Molecular Therapy journal (Nature). This work has made it possible to restore muscle strength in dogs with Duchenne muscular dystrophy, by injecting a "medicine" gene to restore dystrophin production, a protein which is essential for the proper functioning of muscles.
[Press release] CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed. Carlina Technologies is a member of Atlanpole Biotherapies.
ONE Study, a research program of the CESTI University Hospital Institute, applies the innovative concept of cell therapy in the field of organ transplantation. A clinical trial based on this therapy and which aims at limiting the side effects of anti -rejection treatments will start in Nantes by the end of the year.
From May 2014, Clean Cells, an “Atlanpolitan” company, has become a Pharmaceutical Facility, authorized by the French National Security Agency of Medicine and Health Products. This authorization, which concerns the quality control of pharmaceutical products, was extended on October 14th to the production of experimental drugs in biotechnology and cell therapy. This certification opens new and interesting prospects for innovative therapies and biopharmaceuticals onto the drug market.
From 10 to 13 June, a dozen foreign students, selected on the basis of their motivation to put a value on their research, took part in an accelerated training in Nantes. They were led by professionals, to be enabled to create their start-up business. This multicultural group (from England, Eastern Europe, Sweden, China ...) working in the field of biotechnology, studied the themes of intellectual property, finance and funding sources, and finally produced a trial presentation.
Dentaurum Ceramics is the ceramic research and manufacturing center of the Group Dentaurum GmbH and Co.KG, one of the European leaders in orthodontics and dentures. Established since 1994, in France near Angers, Dentaurum Ceramics develops and produces the Dentaurum group’s entire range of dental ceramics.
BioFit is the first European business convention entirely dedicated to Open Innovation, technology transfer and collaborative research in the field of Life Sciences. This international event brings together all professionals in the chain of innovation in the field of Life Sciences (start-up companies, academic research, private research, large companies ...) and thus promotes collaborative public / private R & D projects, and an increase in the number of licensing agreements.
The 3rd Nuclear Technologies for Health Symposium (NTHS) will take place from 10 to 11 March 2015 in Nantes. This international meeting around radiopharmaceuticals and nuclear medicine is organized by the Labex IRON (Radiopharmaceuticals for Innovative Oncology and Neurology Laboratory of Excellence.
The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation.
Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005).